Taken together, the PL-RCA and immunohistochemical data demonstrated significantly increased co-localization of NSUN1, BRD4 and RNA-pol-II CTD-S2P in 5-AZA-resistant MDS/AML cases and a disease progression-associated increase in expression of hnRNPK, NSUN1 and BRD4 in clinical MDS/AML specimens, supporting the clinical importance and relevance of RCMTs and hnRNPK as well as their associated chromatin structures in regulating 5-AZA resistance and disease progression in clinical MDS/AML. The gene discussed is BRD4; the disease is myelodysplastic syndrome.